Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture.
Transcenta is a global biotherapeutic company that fully integrates antibody-based biotherapeutics discovery, R&D and manufacture, focusing on developing innovative antibodies to help more patients. HJB and MabSpace Biosciences merged and created Transcenta.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Nov 29, 2021 | Post-IPO Equity | — | 2 | ARCH Venture Partners Lilly Asia Ventures | — | Detail |
Dec 23, 2020 | Series C | $105M | 1 | — | — | Detail |
Jan 8, 2020 | Series B | $100M | 3 | ARCH Venture Partners | — | Detail |
Jan 2, 2019 | Series Unknown | $137M | 2 | ARCH Venture Partners Lilly Asia Ventures | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Oct 16, 2017
Digital Asset
|
Series B | $40M | Blockchain | — |
Investor Name | Lead Investor | Funding Round |
---|---|---|
ARCH Venture Partners | Yes | Post-IPO Equity |
Lilly Asia Ventures | Yes | Post-IPO Equity |
Yipu Capital | — | Series B |